Evaluation and Management of Patients with Heart Disease and Cancer: Cardio-oncology

Overview

Journal Mayo Clin Proc

Specialty General Medicine

Date 2014 Sep 7

PMID 25192616

Citations 155

Authors

Joerg Herrmann

Amir Lerman

Nicole P Sandhu

Hector R Villarraga

Sharon L Mulvagh

Manish Kohli

Affiliations

Soon will be listed here.

Abstract

The care for patients with cancer has advanced greatly over the past decades. A combination of earlier cancer diagnosis and greater use of traditional and new systemic treatments has decreased cancer-related mortality. Effective cancer therapies, however, can result in short- and long-term comorbidities that can decrease the net clinical gain by affecting quality of life and survival. In particular, cardiovascular complications of cancer treatments can have a profound effect on the health of patients with cancer and are more common among those with recognized or unrecognized underlying cardiovascular diseases. A new discipline termed cardio-oncology has thus evolved to address the cardiovascular needs of patients with cancer and optimize their care in a multidisciplinary approach. This review provides a brief introduction and background on this emerging field and then focuses on its practical aspects including cardiovascular risk assessment and prevention before cancer treatment, cardiovascular surveillance and therapy during cancer treatment, and cardiovascular monitoring and management after cancer therapy. The content of this review is based on a literature search of PubMed between January 1, 1960, and February 1, 2014, using the search terms cancer, cardiomyopathy, cardiotoxicity, cardio-oncology, chemotherapy, heart failure, and radiation.

Citing Articles

Out-of-hospital cardiac arrest event after cancer diagnosis: a korean metropolitan cohort study.

Lee S, Park J, Kim Y, Lee J, Ro Y, Song K BMC Cancer. 2025; 25(1):301.

PMID: 39972256 PMC: 11841187. DOI: 10.1186/s12885-025-13717-9.

The Role of Advanced Cardiac Imaging in Monitoring Cardiovascular Complications in Patients with Extracardiac Tumors: A Descriptive Review.

Tavernese A, Cammalleri V, Mollace R, Antonelli G, Piscione M, Cocco N J Cardiovasc Dev Dis. 2025; 12(1).

PMID: 39852287 PMC: 11765722. DOI: 10.3390/jcdd12010009.

Lung cancer and risk of cardiovascular mortality.

Wang C, Wang Z, Yang J, Zhang S, Zhang P, Yang Y Front Cardiovasc Med. 2025; 11():1491912.

PMID: 39834733 PMC: 11743495. DOI: 10.3389/fcvm.2024.1491912.

Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study.

Kuroda J, Oikawa M, Tokuda E, Tachibana K, Sasaki E, Ohtake T Support Care Cancer. 2024; 33(1):8.

PMID: 39648236 PMC: 11625689. DOI: 10.1007/s00520-024-09067-0.

Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics-Related Cardiac Dysfunction.

Park H, Lee N, Hwang C, Cho S, Choi G, Cho J JACC CardioOncol. 2024; 6(5):699-710.

PMID: 39479323 PMC: 11522502. DOI: 10.1016/j.jaccao.2024.07.018.

References

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G . Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55(3):213-20. DOI: 10.1016/j.jacc.2009.03.095. View

Kruit W, Punt K, Goey S, de Mulder P, Van Hoogenhuyze D, Henzen-Logmans S . Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer. 1994; 74(10):2850-6. DOI: 10.1002/1097-0142(19941115)74:10<2850::aid-cncr2820741018>3.0.co;2-t. View

Choueiri T, Mayer E, Je Y, Rosenberg J, Nguyen P, Azzi G . Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011; 29(6):632-8. DOI: 10.1200/JCO.2010.31.9129. View

cerny J, Hassan A, Smith C, Piperdi B . Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer. 2009; 8(1):55-8. DOI: 10.3816/CCC.2009.n.009. View

Ky B, Putt M, Sawaya H, French B, Januzzi Jr J, Sebag I . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2013; 63(8):809-16. PMC: 4286181. DOI: 10.1016/j.jacc.2013.10.061. View

Schweiger M, Dave H, Lemme F, Cavigelli-Brunner A, Romanchenko O, Heineking B . Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child. ASAIO J. 2013; 59(5):520-2. DOI: 10.1097/MAT.0b013e3182a0d242. View

Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S . Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011; 58(9):988-9. DOI: 10.1016/j.jacc.2011.05.025. View

Minotti G, Cairo G, Monti E . Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. FASEB J. 1999; 13(2):199-212. View

Silber J, Cnaan A, Clark B, Paridon S, Chin A, Rychik J . Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004; 22(5):820-8. DOI: 10.1200/JCO.2004.06.022. View

10.

Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J . Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8):722-31. DOI: 10.1056/NEJMoa1303989. View

11.

O H-Ici D, Garot J . Radiation-induced heart disease. Circ Heart Fail. 2011; 4(1):e1-2. DOI: 10.1161/CIRCHEARTFAILURE.110.958454. View

12.

Ewer M, Lippman S . Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005; 23(13):2900-2. DOI: 10.1200/JCO.2005.05.827. View

13.

Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, DAscenzo F, Malavasi V . Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013; 112(12):1980-4. DOI: 10.1016/j.amjcard.2013.08.026. View

14.

Perez E, Koehler M, Byrne J, Preston A, Rappold E, Ewer M . Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008; 83(6):679-86. DOI: 10.4065/83.6.679. View

15.

Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri M . Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23 Suppl 7:vii155-66. DOI: 10.1093/annonc/mds293. View

16.

Tarantini L, Gori S, Faggiano P, Pulignano G, Simoncini E, Tuccia F . Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol. 2012; 23(12):3058-3063. DOI: 10.1093/annonc/mds127. View

17.

Eder V, Herault S, Hudelo C, Giraudeau B, Marchal C, Quilliet L . Evaluation of left ventricular systolic function by 3D echocardiography: a comparative study with X-ray angiography and radionuclide angiography. Eur J Ultrasound. 2000; 11(2):105-15. DOI: 10.1016/s0929-8266(00)00077-x. View

18.

Serrano C, Cortes J, De Mattos-Arruda L, Bellet M, Gomez P, Saura C . Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2011; 23(4):897-902. DOI: 10.1093/annonc/mdr348. View

19.

Do D, Nguyen Q, Boyer D, Schmidt-Erfurth U, Brown D, Vitti R . One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012; 119(8):1658-65. DOI: 10.1016/j.ophtha.2012.02.010. View

20.

Nousiainen T, Jantunen E, Vanninen E, Hartikainen J . Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002; 86(11):1697-700. PMC: 2375393. DOI: 10.1038/sj.bjc.6600346. View